0001144204-18-028259.txt : 20180613 0001144204-18-028259.hdr.sgml : 20180613 20180514171504 ACCESSION NUMBER: 0001144204-18-028259 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20180514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Synthetic Biologics, Inc. CENTRAL INDEX KEY: 0000894158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133808303 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 617 DETROIT STREET, SUITE 100 CITY: ANN ARBOR STATE: MI ZIP: 48104 BUSINESS PHONE: (734) 332-7800 MAIL ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: ADEONA PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: PIPEX PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20061214 FORMER COMPANY: FORMER CONFORMED NAME: SHEFFIELD PHARMACEUTICALS INC DATE OF NAME CHANGE: 19970730 CORRESP 1 filename1.htm

Synthetic Biologics, Inc.

9605 Medical Center Drive, Suite 270

Rockville, Maryland 20850

May 14, 2018

VIA EDGAR

United States Securities

and Exchange Commission
Division of Corporation Finance

100 F Street, N.E.
Washington, D.C. 20549
Attention: Ms. Dorrie Yale

Re:

Synthetic Biologics, Inc.

Registration Statement on Form S-3

File No: 333-224728

Ladies and Gentlemen:

Synthetic Biologics, Inc. (the “Registrant”) hereby requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-22478), to become effective on Tuesday, May 15, 2018, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The Registrant hereby authorizes its counsel, Leslie Marlow, Esq. of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457 with any questions you may have concerning this request, and please notify her when this request for acceleration has been granted.

	Very truly yours,

	Synthetic Biologics, Inc.

	By: /s/ Steven A. Shallcross
	Name:	Steven A. Shallcross
	Title:	Interim Chief Executive Officer and Chief Financial Officer

cc:

Leslie Marlow, Esq., Gracin & Marlow, LLP

GRAPHIC 2 image_001.jpg GRAPHIC begin 644 image_001.jpg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end